M Sottili1, T Filardi2, G Cantini1,3, L Cosmi4, S Morano2, M Luconi1,3,5, A Lenzi2, C Crescioli6. 1. Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. 2. Department of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. 3. DENOTHE Center of Excellence for Research, Transfer and High Education, University of Florence, 50139, Florence, Italy. 4. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. 5. Istituto Nazionale Biostrutture E Biosistemi (INBB), viale delle Medaglie d'Oro 305, 00136, Rome, Italy. 6. Department of Movement, Human and Health Sciences, Section of Health Sciences, University of Rome "Foro Italico", Piazza L. de Bosis 6, 00135, Rome, Italy. clara.crescioli@uniroma4.it.
Abstract
PURPOSE: The C-X-C motif chemokine ligand 10 (CXCL10) participates in diabetes and diabetic cardiomyopathy development from the early stages. Rosiglitazone (RGZ) exhibits anti-inflammatory properties and can target cardiomyocytes secreting CXCL10, under interferon (IFN)γ and tumor necrosis factor (TNF)α challenge. Cardiomyocyte remodeling, CD4 + T cells and dendritic cells (DCs) significantly contribute to the inflammatory milieu underlying and promoting disease development. We aimed to study the effect of RGZ onto inflammation-induced secretion of CXCL10, IFNγ, TNFα, interleukin (IL)-6 and IL-8 by human CD4 + T and DCs, and onto IFNγ/TNFα-dependent signaling in human cardiomyocytes associated with chemokine release. METHODS: Cells maintained within an inflammatory-like microenvironment were exposed to RGZ at near therapy dose (5 µM). ELISA quantified cytokine secretion; qPCR measured mRNA expression; Western blot analyzed protein expression and activation; immunofluorescent analysis detected intracellular IFNγ/TNFα-dependent trafficking. RESULTS: In human CD4 + T cells and DCs, RGZ inhibited CXCL10 release likely with a transcriptional mechanism, and reduced TNFα only in CD4 + T cells. In human cardiomyocytes, RGZ impaired IFNγ/TNFα signal transduction, blocking the phosphorylation/nuclear translocation of signal transducer and activator of transcription 1 (Stat1) and nuclear factor-kB (NF-kB), in association with a significant decrease in CXCL10 expression, IL-6 and IL-8 release. CONCLUSION: As the combination of Th1 biomarkers like CXCL10, IL-8, IL-6 with classical cardiovascular risk factors seems to improve the accuracy in predicting T2D and coronary events, future studies might be desirable to further investigate the anti-Th1 effect of RGZ.
PURPOSE: The C-X-C motif chemokine ligand 10 (CXCL10) participates in diabetes and diabetic cardiomyopathy development from the early stages. Rosiglitazone (RGZ) exhibits anti-inflammatory properties and can target cardiomyocytes secreting CXCL10, under interferon (IFN)γ and tumor necrosis factor (TNF)α challenge. Cardiomyocyte remodeling, CD4 + T cells and dendritic cells (DCs) significantly contribute to the inflammatory milieu underlying and promoting disease development. We aimed to study the effect of RGZ onto inflammation-induced secretion of CXCL10, IFNγ, TNFα, interleukin (IL)-6 and IL-8 by human CD4 + T and DCs, and onto IFNγ/TNFα-dependent signaling in human cardiomyocytes associated with chemokine release. METHODS: Cells maintained within an inflammatory-like microenvironment were exposed to RGZ at near therapy dose (5 µM). ELISA quantified cytokine secretion; qPCR measured mRNA expression; Western blot analyzed protein expression and activation; immunofluorescent analysis detected intracellular IFNγ/TNFα-dependent trafficking. RESULTS: In human CD4 + T cells and DCs, RGZ inhibited CXCL10 release likely with a transcriptional mechanism, and reduced TNFα only in CD4 + T cells. In human cardiomyocytes, RGZ impaired IFNγ/TNFα signal transduction, blocking the phosphorylation/nuclear translocation of signal transducer and activator of transcription 1 (Stat1) and nuclear factor-kB (NF-kB), in association with a significant decrease in CXCL10 expression, IL-6 and IL-8 release. CONCLUSION: As the combination of Th1 biomarkers like CXCL10, IL-8, IL-6 with classical cardiovascular risk factors seems to improve the accuracy in predicting T2D and coronary events, future studies might be desirable to further investigate the anti-Th1 effect of RGZ.
Authors: J P H van Wijk; M Castro Cabezas; B Coll; J Joven; T J Rabelink; E J P de Koning Journal: Atherosclerosis Date: 2005-08-30 Impact factor: 5.162
Authors: Clara Crescioli; Roberta Squecco; Lorenzo Cosmi; Mariangela Sottili; Stefania Gelmini; Elisa Borgogni; Erica Sarchielli; Sabino Scolletta; Fabio Francini; Francesco Annunziato; Gabriella Barbara Vannelli; Mario Serio Journal: Exp Cell Res Date: 2008-01-04 Impact factor: 3.905
Authors: M Sottili; L Cosmi; E Borgogni; E Sarchielli; L Maggi; M Francalanci; G B Vannelli; E Ronconi; L Adorini; F Annunziato; P Romagnani; M Serio; C Crescioli Journal: Exp Cell Res Date: 2008-11-05 Impact factor: 3.905
Authors: Luigi Di Luigi; Clarissa Corinaldesi; Marta Colletti; Sabino Scolletta; Cristina Antinozzi; Gabriella B Vannelli; Elisa Giannetta; Daniele Gianfrilli; Andrea M Isidori; Silvia Migliaccio; Noemi Poerio; Maurizio Fraziano; Andrea Lenzi; Clara Crescioli Journal: Inflammation Date: 2016-06 Impact factor: 4.092
Authors: S Giannattasio; C Corinaldesi; M Colletti; L Di Luigi; C Antinozzi; T Filardi; S Scolletta; S Basili; A Lenzi; S Morano; C Crescioli Journal: J Endocrinol Invest Date: 2018-11-10 Impact factor: 4.256
Authors: Silvia Giannattasio; Anna Citarella; Sofia Trocchianesi; Tiziana Filardi; Susanna Morano; Andrea Lenzi; Elisabetta Ferretti; Clara Crescioli Journal: Front Mol Biosci Date: 2022-05-31